Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Waldenstrom Macroglobulinemia | 117 | 2024 | 1052 | 11.930 |
Why?
|
Myeloid Differentiation Factor 88 | 46 | 2023 | 571 | 6.170 |
Why?
|
Receptors, CXCR4 | 28 | 2021 | 726 | 3.280 |
Why?
|
Adenine | 28 | 2024 | 936 | 2.100 |
Why?
|
Pyrazoles | 21 | 2022 | 1972 | 1.750 |
Why?
|
Piperidines | 28 | 2024 | 1602 | 1.610 |
Why?
|
Pyrimidines | 21 | 2022 | 2942 | 1.550 |
Why?
|
Immunoglobulin M | 27 | 2021 | 1537 | 1.420 |
Why?
|
Mutation | 39 | 2023 | 29786 | 1.110 |
Why?
|
Chromosome Deletion | 2 | 2020 | 1401 | 0.960 |
Why?
|
Chromosomes, Human, Pair 6 | 2 | 2020 | 380 | 0.760 |
Why?
|
Lymphoma, B-Cell | 4 | 2022 | 931 | 0.670 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2020 | 460 | 0.630 |
Why?
|
Proto-Oncogene Proteins c-hck | 5 | 2022 | 46 | 0.620 |
Why?
|
Chemokine CXCL13 | 1 | 2017 | 54 | 0.610 |
Why?
|
Protein Kinase Inhibitors | 8 | 2021 | 5535 | 0.530 |
Why?
|
Signal Transduction | 18 | 2020 | 23403 | 0.520 |
Why?
|
B-Lymphocytes | 13 | 2022 | 4665 | 0.490 |
Why?
|
Point Mutation | 3 | 2021 | 1623 | 0.470 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5172 | 0.460 |
Why?
|
Warts | 1 | 2013 | 68 | 0.460 |
Why?
|
Boronic Acids | 6 | 2012 | 965 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11524 | 0.430 |
Why?
|
Genomics | 4 | 2020 | 5720 | 0.420 |
Why?
|
Pyrazines | 6 | 2012 | 1230 | 0.390 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13695 | 0.370 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2013 | 547 | 0.360 |
Why?
|
Bone Marrow | 10 | 2021 | 2948 | 0.350 |
Why?
|
Blood Viscosity | 5 | 2019 | 124 | 0.330 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2013 | 365 | 0.330 |
Why?
|
Agammaglobulinemia | 1 | 2009 | 167 | 0.320 |
Why?
|
Sulfonamides | 3 | 2024 | 1938 | 0.290 |
Why?
|
NF-kappa B | 6 | 2020 | 2499 | 0.280 |
Why?
|
Humans | 127 | 2024 | 744343 | 0.280 |
Why?
|
Immunoglobulin A | 1 | 2009 | 992 | 0.270 |
Why?
|
Gene Deletion | 1 | 2013 | 2751 | 0.270 |
Why?
|
Neoplasm Proteins | 5 | 2019 | 3703 | 0.260 |
Why?
|
Aged | 54 | 2024 | 163280 | 0.260 |
Why?
|
Aged, 80 and over | 32 | 2021 | 57776 | 0.250 |
Why?
|
Apoptosis | 11 | 2020 | 9727 | 0.250 |
Why?
|
Iron | 1 | 2013 | 1774 | 0.250 |
Why?
|
Sp1 Transcription Factor | 2 | 2016 | 144 | 0.240 |
Why?
|
Middle Aged | 62 | 2021 | 213383 | 0.240 |
Why?
|
Quinazolinones | 2 | 2016 | 221 | 0.240 |
Why?
|
Plasma Cells | 5 | 2022 | 591 | 0.240 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2023 | 2649 | 0.230 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2019 | 2942 | 0.230 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 10 | 2014 | 693 | 0.220 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2015 | 177 | 0.220 |
Why?
|
Receptors, IgE | 1 | 2005 | 389 | 0.220 |
Why?
|
Purines | 3 | 2016 | 594 | 0.220 |
Why?
|
Amino Acid Substitution | 5 | 2019 | 1791 | 0.220 |
Why?
|
Neprilysin | 1 | 2005 | 439 | 0.210 |
Why?
|
Receptors, IgG | 4 | 2011 | 582 | 0.210 |
Why?
|
Survival Rate | 11 | 2021 | 12788 | 0.200 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6895 | 0.200 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 625 | 0.200 |
Why?
|
Antibodies, Monoclonal | 11 | 2020 | 9274 | 0.190 |
Why?
|
Male | 60 | 2021 | 350118 | 0.190 |
Why?
|
Lymphoproliferative Disorders | 2 | 2014 | 523 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2017 | 2455 | 0.180 |
Why?
|
Phospholipase C gamma | 1 | 2020 | 128 | 0.180 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1378 | 0.180 |
Why?
|
Immunoglobulin G | 3 | 2014 | 4560 | 0.170 |
Why?
|
Treatment Outcome | 23 | 2020 | 63114 | 0.170 |
Why?
|
Paraproteinemias | 2 | 2012 | 246 | 0.170 |
Why?
|
Multiple Myeloma | 4 | 2021 | 5181 | 0.160 |
Why?
|
Female | 56 | 2021 | 380194 | 0.160 |
Why?
|
Nucleosides | 2 | 2009 | 138 | 0.160 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 86 | 0.160 |
Why?
|
p21-Activated Kinases | 1 | 2018 | 128 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8428 | 0.150 |
Why?
|
Antibodies, Neoplasm | 2 | 2011 | 286 | 0.150 |
Why?
|
Adult | 37 | 2021 | 214055 | 0.150 |
Why?
|
Neoplasms, Second Primary | 2 | 2015 | 1061 | 0.150 |
Why?
|
Plasma | 1 | 2020 | 575 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2015 | 1381 | 0.140 |
Why?
|
Acrylamides | 1 | 2018 | 255 | 0.140 |
Why?
|
Paracrine Communication | 1 | 2018 | 277 | 0.140 |
Why?
|
DNA Methylation | 3 | 2020 | 4286 | 0.130 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 101 | 0.130 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2011 | 789 | 0.130 |
Why?
|
Cyclophilin A | 1 | 2015 | 57 | 0.130 |
Why?
|
SEER Program | 3 | 2015 | 1508 | 0.130 |
Why?
|
Cell Proliferation | 7 | 2018 | 10481 | 0.130 |
Why?
|
Epigenomics | 1 | 2020 | 903 | 0.130 |
Why?
|
Aminopyridines | 1 | 2018 | 542 | 0.120 |
Why?
|
Cytokines | 3 | 2018 | 7322 | 0.120 |
Why?
|
Cell Survival | 8 | 2018 | 5882 | 0.120 |
Why?
|
Prognosis | 11 | 2021 | 29063 | 0.120 |
Why?
|
von Willebrand Factor | 1 | 2018 | 669 | 0.120 |
Why?
|
Gene Expression Profiling | 5 | 2016 | 9438 | 0.120 |
Why?
|
Drug Tolerance | 1 | 2015 | 376 | 0.120 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 1941 | 0.120 |
Why?
|
Vidarabine | 2 | 2012 | 345 | 0.120 |
Why?
|
Codon, Nonsense | 1 | 2014 | 281 | 0.110 |
Why?
|
Antigens, CD | 3 | 2011 | 4026 | 0.110 |
Why?
|
Thalidomide | 2 | 2009 | 890 | 0.110 |
Why?
|
Translocation, Genetic | 2 | 2021 | 1420 | 0.110 |
Why?
|
Survival Analysis | 8 | 2020 | 10252 | 0.110 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2016 | 548 | 0.110 |
Why?
|
Disease Progression | 6 | 2021 | 13284 | 0.110 |
Why?
|
Frameshift Mutation | 1 | 2014 | 399 | 0.110 |
Why?
|
Cell Line, Tumor | 10 | 2021 | 16689 | 0.110 |
Why?
|
Gene Expression | 6 | 2019 | 7799 | 0.110 |
Why?
|
Lymphoma | 1 | 2021 | 1877 | 0.110 |
Why?
|
Comparative Genomic Hybridization | 1 | 2013 | 496 | 0.110 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2703 | 0.100 |
Why?
|
Transferrin | 1 | 2013 | 295 | 0.100 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2012 | 83 | 0.100 |
Why?
|
Hydroxamic Acids | 2 | 2011 | 494 | 0.100 |
Why?
|
Mice, SCID | 5 | 2021 | 2716 | 0.100 |
Why?
|
Transcriptional Activation | 2 | 2016 | 1783 | 0.100 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6171 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2017 | 2727 | 0.100 |
Why?
|
Matrix Metalloproteinase 8 | 1 | 2011 | 56 | 0.100 |
Why?
|
Alleles | 3 | 2019 | 6933 | 0.100 |
Why?
|
Cyclophosphamide | 3 | 2012 | 2242 | 0.100 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39050 | 0.100 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 1988 | 0.090 |
Why?
|
Glycoproteins | 2 | 2011 | 2263 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1526 | 0.090 |
Why?
|
Mast Cells | 3 | 2008 | 1544 | 0.090 |
Why?
|
Bone Marrow Cells | 3 | 2011 | 2513 | 0.090 |
Why?
|
Cell Communication | 1 | 2018 | 1621 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6538 | 0.090 |
Why?
|
Anemia | 2 | 2011 | 1506 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 987 | 0.090 |
Why?
|
Ubiquitins | 1 | 2012 | 384 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1017 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3597 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1157 | 0.090 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2019 | 1880 | 0.080 |
Why?
|
Antigens, CD20 | 2 | 2007 | 199 | 0.080 |
Why?
|
Tunicamycin | 1 | 2008 | 112 | 0.080 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2011 | 362 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2014 | 685 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2018 | 2564 | 0.080 |
Why?
|
Boron Compounds | 2 | 2020 | 178 | 0.080 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 697 | 0.080 |
Why?
|
Lymphocytes | 2 | 2013 | 2617 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2948 | 0.080 |
Why?
|
Central Nervous System Neoplasms | 1 | 2016 | 895 | 0.080 |
Why?
|
Genes, Regulator | 1 | 2009 | 378 | 0.080 |
Why?
|
Promoter Regions, Genetic | 2 | 2016 | 5867 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2503 | 0.080 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 1708 | 0.070 |
Why?
|
Sequence Analysis, DNA | 3 | 2015 | 4803 | 0.070 |
Why?
|
Hepatitis C Antibodies | 1 | 2007 | 145 | 0.070 |
Why?
|
Family Health | 1 | 2011 | 1282 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9648 | 0.070 |
Why?
|
Stress, Physiological | 2 | 2011 | 1403 | 0.070 |
Why?
|
Dexamethasone | 3 | 2020 | 1951 | 0.070 |
Why?
|
Flow Cytometry | 5 | 2013 | 5974 | 0.070 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 307 | 0.070 |
Why?
|
Glycine | 2 | 2020 | 671 | 0.070 |
Why?
|
Transcription Factors | 3 | 2015 | 12208 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2015 | 7880 | 0.070 |
Why?
|
Blood Proteins | 1 | 2011 | 1124 | 0.070 |
Why?
|
Simvastatin | 1 | 2008 | 360 | 0.070 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 2 | 2017 | 78 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3647 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2013 | 4740 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2022 | 2916 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2149 | 0.060 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 4186 | 0.060 |
Why?
|
Biopsy | 3 | 2019 | 6756 | 0.060 |
Why?
|
CD40 Ligand | 1 | 2006 | 526 | 0.060 |
Why?
|
Prospective Studies | 8 | 2021 | 53288 | 0.060 |
Why?
|
Mastocytosis | 1 | 2006 | 160 | 0.060 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 18111 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2007 | 791 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 272 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6314 | 0.060 |
Why?
|
Mice, Inbred NOD | 2 | 2021 | 1878 | 0.050 |
Why?
|
Polymorphism, Genetic | 3 | 2011 | 4328 | 0.050 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 1144 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2245 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 1434 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4554 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 5 | 2019 | 17446 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13815 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2008 | 1366 | 0.050 |
Why?
|
Protein Multimerization | 2 | 2017 | 970 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12959 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 15519 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2007 | 2421 | 0.050 |
Why?
|
Retinal Vessels | 1 | 2006 | 772 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6544 | 0.050 |
Why?
|
Retrospective Studies | 10 | 2020 | 77449 | 0.050 |
Why?
|
Retinal Diseases | 1 | 2006 | 683 | 0.050 |
Why?
|
Vasodilator Agents | 1 | 2004 | 977 | 0.050 |
Why?
|
Incidence | 6 | 2016 | 20947 | 0.050 |
Why?
|
Paraproteins | 1 | 2020 | 39 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3798 | 0.040 |
Why?
|
Antigens, CD19 | 2 | 2014 | 380 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2015 | 3557 | 0.040 |
Why?
|
MicroRNAs | 1 | 2016 | 3752 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2022 | 551 | 0.040 |
Why?
|
Hepacivirus | 1 | 2007 | 1379 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 2382 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2020 | 315 | 0.040 |
Why?
|
Animals | 12 | 2021 | 168757 | 0.040 |
Why?
|
Genome, Human | 1 | 2012 | 4420 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2019 | 9734 | 0.040 |
Why?
|
Genotype | 4 | 2017 | 12951 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8089 | 0.040 |
Why?
|
Germinal Center | 1 | 2021 | 377 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12354 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2013 | 5853 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18029 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2008 | 1352 | 0.040 |
Why?
|
Case-Control Studies | 5 | 2020 | 21746 | 0.040 |
Why?
|
Hemoglobins | 2 | 2015 | 1534 | 0.040 |
Why?
|
RNA, Viral | 1 | 2007 | 2902 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9583 | 0.040 |
Why?
|
Mice | 8 | 2021 | 81183 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2007 | 2133 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2018 | 189 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2007 | 1580 | 0.040 |
Why?
|
Phosphorylation | 3 | 2016 | 8436 | 0.040 |
Why?
|
Protein Binding | 3 | 2017 | 9386 | 0.040 |
Why?
|
Drug Synergism | 2 | 2015 | 1792 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2011 | 4933 | 0.040 |
Why?
|
Cell Line | 2 | 2011 | 15997 | 0.040 |
Why?
|
Hematocrit | 2 | 2011 | 636 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2020 | 326 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2014 | 3701 | 0.040 |
Why?
|
Plasmapheresis | 1 | 2017 | 211 | 0.040 |
Why?
|
Cohort Studies | 3 | 2015 | 40561 | 0.040 |
Why?
|
von Willebrand Diseases | 1 | 2018 | 127 | 0.040 |
Why?
|
Hepatitis C | 1 | 2007 | 1591 | 0.030 |
Why?
|
Immunoblotting | 2 | 2011 | 1682 | 0.030 |
Why?
|
Histone Deacetylases | 2 | 2011 | 728 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2009 | 3523 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4751 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5686 | 0.030 |
Why?
|
Histocytochemistry | 1 | 2016 | 719 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6773 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7913 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3870 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 528 | 0.030 |
Why?
|
Vincristine | 2 | 2009 | 1039 | 0.030 |
Why?
|
Octamer Transcription Factor-2 | 1 | 2014 | 7 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2016 | 563 | 0.030 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2014 | 32 | 0.030 |
Why?
|
Blotting, Western | 2 | 2013 | 5179 | 0.030 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 180 | 0.030 |
Why?
|
Piperazines | 1 | 2004 | 2488 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2016 | 500 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2024 | 2268 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 594 | 0.030 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 592 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 474 | 0.030 |
Why?
|
Cells, Cultured | 4 | 2013 | 19229 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1609 | 0.030 |
Why?
|
Caspase 3 | 1 | 2016 | 758 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3255 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12797 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2014 | 464 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1692 | 0.030 |
Why?
|
Prednisone | 2 | 2009 | 1574 | 0.030 |
Why?
|
Neoplasms | 2 | 2011 | 21683 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11124 | 0.030 |
Why?
|
Age of Onset | 1 | 2018 | 3271 | 0.030 |
Why?
|
Neutropenia | 2 | 2009 | 895 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2016 | 1547 | 0.030 |
Why?
|
Stem Cells | 1 | 2005 | 3567 | 0.030 |
Why?
|
Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 733 | 0.020 |
Why?
|
Leucine | 1 | 2013 | 561 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2018 | 1275 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 893 | 0.020 |
Why?
|
Proline | 1 | 2013 | 458 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2013 | 905 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13102 | 0.020 |
Why?
|
Doxorubicin | 2 | 2009 | 2234 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3586 | 0.020 |
Why?
|
Lentivirus | 1 | 2013 | 501 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3129 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2011 | 403 | 0.020 |
Why?
|
Risk Factors | 3 | 2017 | 72290 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18370 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2085 | 0.020 |
Why?
|
beta Catenin | 1 | 2015 | 1059 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2011 | 647 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 873 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1655 | 0.020 |
Why?
|
Chlorambucil | 1 | 2008 | 43 | 0.020 |
Why?
|
Gene Silencing | 1 | 2016 | 1538 | 0.020 |
Why?
|
Cladribine | 1 | 2008 | 34 | 0.020 |
Why?
|
Electrophoresis, Capillary | 1 | 2009 | 64 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1889 | 0.020 |
Why?
|
United States | 4 | 2021 | 69872 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1119 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6386 | 0.020 |
Why?
|
Time Factors | 3 | 2021 | 40075 | 0.020 |
Why?
|
Plasmids | 1 | 2014 | 2307 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2011 | 1095 | 0.020 |
Why?
|
Oligopeptides | 1 | 2014 | 1189 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4204 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2386 | 0.020 |
Why?
|
DNA Damage | 1 | 2018 | 2432 | 0.020 |
Why?
|
Cell Death | 1 | 2014 | 1706 | 0.020 |
Why?
|
Immunotherapy | 2 | 2016 | 4445 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 3002 | 0.020 |
Why?
|
Caspases | 1 | 2011 | 928 | 0.020 |
Why?
|
Drug Discovery | 1 | 2016 | 1058 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2011 | 881 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20822 | 0.020 |
Why?
|
Phosphorylcholine | 1 | 2008 | 162 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2011 | 638 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2938 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10943 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 1012 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2889 | 0.020 |
Why?
|
Binding Sites | 1 | 2016 | 6114 | 0.020 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2006 | 242 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2016 | 3200 | 0.020 |
Why?
|
Ophthalmoscopy | 1 | 2006 | 176 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11366 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 5456 | 0.020 |
Why?
|
Interphase | 1 | 2005 | 226 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2016 | 3768 | 0.020 |
Why?
|
Protein Folding | 1 | 2008 | 843 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13408 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2014 | 11483 | 0.020 |
Why?
|
Trans-Activators | 1 | 2014 | 2924 | 0.010 |
Why?
|
Heterozygote | 1 | 2011 | 2804 | 0.010 |
Why?
|
Models, Genetic | 1 | 2014 | 3494 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3505 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2011 | 2715 | 0.010 |
Why?
|
Karyotyping | 1 | 2005 | 1243 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5097 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2886 | 0.010 |
Why?
|
Pedigree | 1 | 2011 | 4644 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5217 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2006 | 1423 | 0.010 |
Why?
|
Transfection | 1 | 2011 | 5892 | 0.010 |
Why?
|
Cell Cycle | 1 | 2011 | 2967 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2006 | 1341 | 0.010 |
Why?
|
Sulfones | 1 | 2004 | 437 | 0.010 |
Why?
|
Tumor Burden | 1 | 2008 | 1915 | 0.010 |
Why?
|
Health Surveys | 1 | 2011 | 4037 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10397 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3086 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2009 | 1179 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 12072 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11031 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 9239 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8663 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3772 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2008 | 2728 | 0.010 |
Why?
|
Graft Survival | 1 | 2007 | 3737 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 56430 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8340 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7722 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 35421 | 0.010 |
Why?
|